MDT-AP-1344
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- new_clusters
- S3
- umap1_2d
- -1.349962104
- umap2_2d
- -8.349199204
- umap1_3d
- -2.769019562
- umap2_3d
- -2.424896099
- umap3_3d
- 5.990293471
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.420
- HYPOXIA+0.390
- INFLAMMATORY_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.340
- COMPLEMENT+0.330
- KRAS_SIGNALING_DN+0.320
- COAGULATION+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- ALLOGRAFT_REJECTION+0.290
- APICAL_SURFACE+0.270
Top 10 suppressed
- G2M_CHECKPOINT-0.550
- E2F_TARGETS-0.500
- MITOTIC_SPINDLE-0.450
- MYC_TARGETS_V2-0.390
- DNA_REPAIR-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.280
- PEROXISOME-0.270
- MYC_TARGETS_V1-0.260
- PROTEIN_SECRETION-0.260
- TGF_BETA_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TDEFAPNH | DNET | — | 0.910 |
| 2 | MDT-AP-2130 | Med | Medulloblastoma | 0.909 |
| 3 | SRR1797289 | — | cohortMD2 | 0.902 |
| 4 | SRR1797250 | — | cohortMD2 | 0.896 |
| 5 | MDT-AP-2892 | Med | Medulloblastoma | 0.888 |
| 6 | SRR1335707 | GTEX | — | 0.888 |
| 7 | MDT-AP-0567 | Med | Medulloblastoma | 0.888 |
| 8 | MDT-AP-2495 | Med | Medulloblastoma | 0.885 |
| 9 | SRR1322456 | GTEX | — | 0.880 |
| 10 | SRR1359171 | GTEX | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| HYPOXIA | 0.390 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |